Car-nk Cells
Car-nk Cells - Related Videos
11:02
Natural Killer (NK) and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line
0 Views •
Cited by 7 •
2022
Here, we present a method to expand peripheral blood natural killer (PBNK), NK cells from liver tissues, and chimeric antigen receptor (CAR)-NK cells derived from peripheral blood mononuclear cells (PBMCs) or cord blood (CB). This protocol demonstrates the expansion of NK and CAR-NK cells using 221-mIL-21 feeder cells in addition to the optimized purity of expanded NK cells.
08:17
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
0 Views •
Cited by 12 •
2016
A simple and reliable method is described here to analyze a set of NK cell functions such as degranulation, cytokine and chemokine production within different NK cell subsets.
13:18
Quantifying NK-Cell Cytotoxicity Potentiated by Chimeric Antigen Receptors and Therapeutic Antibodies Using Live-Cell Imaging and Flow Cytometry
0 Views •
2026
This protocol provides a standardized in vitro. workflow for consistent measurement of natural, chimeric antigen receptor–mediated, and antibody-dependent cytotoxicity of human natural killer cells using live-cell imaging and flow cytometry.
02:55
Genetically Modifying CAR T Cells Using a CRISPR-Cas9 System
0 Views •
2025
The video outlines a process for creating genetically modified CAR T cells through the CRISPR-Cas9 System. Infecting T cells with CRISPR and CAR lentiviruses results in modifications to the target gene and the synthesis of a chimeric antigen receptor or CAR, ultimately leading to the formation of genetically modified CAR T cells.
03:32
A Technique for the Generation of Antigen-Specific CAR T Cells
0 Views •
2025
This video demonstrates a technique for generating antigen-specific chimeric antigen receptor (CAR) T cells through retroviral transduction. Activated murine CD8+ T cells are added to a microwell plate coated with recombinant fibronectin fragments. Retroviral vectors containing transgenic RNA encoding an antigen-specific chimeric antigen receptor (CAR) are then introduced, and the plate is centrifuged to facilitate transduction. After incubation, the transduced cells express antigen-specific...
FAQs
When the CAR binds its selected surface antigen, its signaling domains activate NK-cell effector functions. These responses include degranulation and cytokine release, along with cytotoxic activity mediated by perforin and granzymes. Together, these mechanisms provide a targeted route for damaging recognized diseased cells while retaining characteristic innate immune activity.
The chimeric antigen receptor is designed to bind a chosen surface antigen directly, so recognition can occur without relying on conventional major histocompatibility complex presentation. This feature distinguishes the CAR-directed recognition route from mechanisms that depend on antigen presentation and supports investigation of targets that can be identified through accessible cell-surface markers.
Their appeal comes from combining targeted antigen recognition with NK-cell-mediated cytotoxicity, while also offering potential for scalable manufacturing and reduced graft-versus-host reactivity. These characteristics support research into cellular therapies that could be adapted to different diseased-cell targets and investigated as potentially safer alternatives within targeted immunotherapy development.
A study begins by selecting a surface antigen associated with the diseased cells, then genetically engineering NK cells to express a corresponding chimeric antigen receptor. Researchers can subsequently examine receptor-triggered degranulation, cytokine release, and perforin- and granzyme-mediated cytotoxicity. This workflow connects receptor design with measurable immune-cell functions.
The selected surface antigen determines which diseased cells the engineered receptor can recognize. Because CAR signaling depends on binding that antigen, target selection directly shapes the specificity of the response and the cells available for investigation. In cancer or infection studies, this links receptor design to the intended disease-associated cell population.
CAR-NK cells are being studied as platforms for targeted cellular therapies against cancer and selected virus-infected cells. In these settings, researchers can evaluate whether engineered recognition elicits NK-cell degranulation, cytokine release, and cytotoxicity against the relevant diseased population. Their potential scalability and reduced graft-versus-host reactivity further support continued investigation.